Live feed06:05:00·150dPRReleasevia QuantisnowMannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime TherapyByQuantisnow·Wall Street's wire, on your screen.MNKD· MannKind CorporationHealth Care
